バイオマーカー臨床段階アウトソーシングサービス市場規模、シェア、動向分析レポート：バイオマーカータイプ別、治療分野別、最終用途別、地域別、セグメント別予測、2023年～2030年

バイオマーカー臨床フェーズアウトソーシングサービス市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、バイオマーカー臨床フェーズアウトソーシングサービスの世界市場規模は2030年までに271億7,000万米ドルに達し、CAGR 20.6%を記録する見込みです。

バイオマーカーの診断用途の増加、OMICS技術の急速な進歩、政府からの研究開発（R&D）資金の増加、精密医療へのシフトは、市場の成長を促進する要因のいくつかです。

市場は断片化されており、複数の主要企業が同様の技術力と処理能力を有しています。これらの企業は、アッセイ開発、サンプル分析、データ解釈、臨床試験サポートなど、バイオマーカー検査に関するさまざまなサービスを提供しています。この業界は、品質保証、技術の進歩、規制への対応、高価値で多様なサービスを提供する能力などの要因による激しい競合が特徴です。

バイオマーカーは個別化医療の中核であり、より良い患者ケアとより効果的な治療を可能にします。したがって、精密医療へのシフトもバイオマーカー検査サービスの需要を支える重要な要因の1つであり、それによって市場の成長が増大します。例えば、2022年1月、Pfizer Inc.とBeam Therapeutics Inc.は、希少遺伝性疾患に対する精密医療を開発するための独占的な4年間の共同研究契約を発表しました。

COVID-19パンデミックは市場に中程度の影響を与えました。COVID-19パンデミックの初期段階は、バイオマーカー検査サービスを含む臨床試験を含む渡航制限により、臨床試験に大きな影響を与えました。しかし、COVID-19診断用バイオマーカーの急速な開拓により、市場は損失から回復しました。ウイルスRNAを標的とするPCRアッセイやウイルスタンパク質を検出する抗原検査などのバイオマーカーに基づく検査は、ウイルスの特定と追跡に極めて重要です。

バイオマーカー臨床段階アウトソーシングサービス市場レポートハイライト

• バイオマーカーの種類別では、代替エンドポイント分野が2022年に56.0%の最大シェアを占めました。同分野の成長を牽引しているのは、精密医薬品に対する需要の高まりと、バイオマーカー解析を用いた臨床試験件数の増加です。
• 治療分野別では、がん領域が2022年に34.6%の最大シェアを占めました。同分野のシェアが高い主な理由は、がんの早期発見と診断のためのがんバイオマーカーの需要が増加しているためです。
• バイオテクノロジー企業は、新規バイオマーカー検査サービスの開発に投資するバイオ製薬企業が増加していることから、分析期間を通じて20.8%のCAGRが見込まれます。
• アジア太平洋地域は、予測期間中に21.4%という最高のCAGRを記録すると予測されています。高い成長は主に、中国やインドなどの新興経済諸国に製造活動をアウトソーシングする欧米の製薬企業の増加によるものです。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 バイオマーカー臨床段階アウトソーシングサービス市場変数、動向および範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• バイオマーカー臨床段階アウトソーシングサービス市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析
  • COVID-19感染症の影響分析

第4章 バイオマーカー臨床段階アウトソーシングサービス市場：バイオマーカーの種類の推定・動向分析

• バイオマーカー臨床段階アウトソーシングサービス市場、バイオマーカータイプ別：セグメントダッシュボード
• バイオマーカー臨床段階アウトソーシングサービス市場、バイオマーカータイプ別：変動分析

第5章 バイオマーカー臨床段階アウトソーシングサービス市場：治療領域の推定・動向分析

• バイオマーカー臨床段階アウトソーシングサービス市場、治療分野別：セグメントダッシュボード
• バイオマーカー臨床段階アウトソーシングサービス市場、治療分野別：変動分析

第6章 バイオマーカー臨床段階アウトソーシングサービス市場：最終用途の推定・動向分析

• バイオマーカー臨床段階アウトソーシングサービス市場、最終用途別：セグメントダッシュボード
• バイオマーカー臨床段階アウトソーシングサービス市場、最終用途別：変動分析

第7章 バイオマーカー臨床段階アウトソーシングサービス市場：地域推定・動向分析

• 地域市場シェア分析、2022年および2030年
• 地域市場ダッシュボード
• 世界の地域市場のスナップショット
• 北米
  • 市場推計・予測、2018～2030年
  • 米国
  • カナダ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋地域
  • 日本
  • インド
  • 中国
  • 韓国
  • オーストラリア
  • タイ
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 市場参入企業の分類
  • イノベーター
  • マーケットリーダー
  • 新興プレイヤー
  • 企業の市場シェア分析、2022年
• 企業プロファイル
  • Laboratory Corporation of America Holdings
  • Parexel International Corporation
  • ICON plc
  • Charles River Laboratories
  • Proteome Sciences
  • Fujirebio
  • WuXi AppTec
  • NorthEast BioAnalytical Laboratories LLC.
  • Celerion
  • GenScript ProBio

List of Tables

• Table 1 List of secondary sources
• Table 2 List of Abbreviations
• Table 3 North America Biomarker Clinical Phase Outsourcing Services market, by region, 2018 - 2030 (USD Million)
• Table 4 North America Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 5 North America Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
• Table 6 North America Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
• Table 7 U.S. Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 8 U.S. Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
• Table 9 U.S. Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
• Table 10 Canada Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 11 Canada Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
• Table 12 Canada Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
• Table 13 Europe Biomarker Clinical Phase Outsourcing Services market, by region, 2018 - 2030 (USD Million)
• Table 14 Europe Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 15 Europe Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
• Table 16 Europe Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
• Table 17 UK Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 18 UK Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
• Table 19 UK Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
• Table 20 Germany Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 21 Germany Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
• Table 22 Germany Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
• Table 23 France Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 24 France Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
• Table 25 France Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
• Table 26 Italy Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 27 Italy Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
• Table 28 Italy Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
• Table 29 Spain Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area type, 2018 - 2030 (USD Million)
• Table 30 Spain Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
• Table 31 Spain Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
• Table 32 Denmark Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 33 Denmark Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
• Table 34 Denmark Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
• Table 35 Sweden Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 36 Sweden Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
• Table 37 Sweden Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
• Table 38 Norway Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 39 Norway Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
• Table 40 Norway Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
• Table 41 Asia Pacific Biomarker Clinical Phase Outsourcing Services market, by region, 2018 - 2030 (USD Million)
• Table 42 Asia Pacific Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 43 Asia Pacific Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
• Table 44 Asia Pacific Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
• Table 45 China Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 46 China Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
• Table 47 China Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
• Table 48 Japan Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 49 Japan Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
• Table 50 Japan Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
• Table 51 India Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 52 India Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
• Table 53 Australia Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 54 Australia Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
• Table 55 Australia Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
• Table 56 South Korea Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 57 South Korea Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
• Table 58 South Korea Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
• Table 59 Thailand Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
• Table 60 Thailand Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 61 Thailand Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
• Table 62 Latin America Biomarker Clinical Phase Outsourcing Services market, by region, 2018 - 2030 (USD Million)
• Table 63 Latin America Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 64 Latin America Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
• Table 65 Latin America Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
• Table 66 Brazil Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 67 Brazil Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
• Table 68 Brazil Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
• Table 69 Mexico Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 70 Mexico Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
• Table 71 Mexico Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
• Table 72 Argentina Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 73 Argentina Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
• Table 74 Argentina Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
• Table 75 Middle East and Africa Biomarker Clinical Phase Outsourcing Services market, by region, 2018 - 2030 (USD Million)
• Table 76 Middle East and Africa Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 77 Middle East and Africa Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
• Table 78 Middle East and Africa Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
• Table 79 South Africa Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 80 South Africa Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
• Table 81 South Africa Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
• Table 82 Saudi Arabia Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 83 Saudi Arabia Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
• Table 84 Saudi Arabia Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
• Table 85 UAE Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 86 UAE Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
• Table 87 UAE Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
• Table 88 Kuwait Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 89 Kuwait Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
• Table 90 Kuwait Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Information procurement
• Fig. 3 Market research approaches
• Fig. 4 QFD modeling for market share assessment
• Fig. 5 Market formulation & validation
• Fig. 6 Commodity flow analysis
• Fig. 7 Primary research pattern
• Fig. 8 Primary interviews in North America
• Fig. 9 Primary interviews in Europe
• Fig. 10 Primary interviews in Asia Pacific
• Fig. 11 Primary interviews in Latin America
• Fig. 12 Primary interviews in MEA
• Fig. 13 Market Snapshot
• Fig. 14 Segment Snapshot
• Fig. 15 Segment Snapshot
• Fig. 16 Competitive Landscape Snapshot
• Fig. 17 Biomarker Clinical Phase Outsourcing Services market segmentation
• Fig. 18 Parent market outlook (2022)
• Fig. 19 Related/ancillary market outlook (2022)
• Fig. 20 Market driver relevance analysis (Current & future impact)
• Fig. 21 Current shared services and outsourcing usage levels
• Fig. 22 Market restraint relevance analysis (Current & future impact)
• Fig. 23 Porter's five forces analysis
• Fig. 24 SWOT analysis, by a factor (political & legal, economic and technological)
• Fig. 25 Biomarker Clinical Phase Outsourcing Services Market Biomarker Type outlook: Segment dashboard
• Fig. 26 Biomarker Clinical Phase Outsourcing Services: Biomarker Type movement analysis
• Fig. 27 Predictive Biomarkers market, 2018 - 2030 (USD Million)
• Fig. 28 Prognostic Biomarkers market, 2018 - 2030 (USD Million)
• Fig. 29 Safety Biomarkers market, 2018 - 2030 (USD Million)
• Fig. 30 Surrogate Endpoints market, 2018 - 2030 (USD Million)
• Fig. 31 Biomarker Clinical Phase Outsourcing Services Market Therapeutic Area outlook: Segment dashboard
• Fig. 32 Biomarker Clinical Phase Outsourcing Services: Therapeutic Area type movement analysis
• Fig. 33 Oncology market, 2018 - 2030 (USD Million)
• Fig. 34 Neurology market, 2018 - 2030 (USD Million)
• Fig. 35 Cardiology market, 2018 - 2030 (USD Million)
• Fig. 36 Autoimmune Diseases market, 2018 - 2030 (USD Million)
• Fig. 37 Others market, 2018 - 2030 (USD Million)
• Fig. 38 Biomarker Clinical Phase Outsourcing Services market End-use outlook: Segment dashboard
• Fig. 39 Biomarker Clinical Phase Outsourcing Services market: End-use movement analysis
• Fig. 40 Pharmaceutical Companies market, 2018 - 2030 (USD Million)
• Fig. 41 Biotechnology Companies market, 2018 - 2030 (USD Million)
• Fig. 42 Others market, 2018 - 2030 (USD Million)
• Fig. 43 Regional marketplace: Segment dashboard
• Fig. 44 Regional outlook, 2022 & 2030
• Fig. 45 North America market, 2018 - 2030 (USD Million)
• Fig. 46 U.S. market, 2018 - 2030 (USD Million)
• Fig. 47 Canada market, 2018 - 2030 (USD Million)
• Fig. 48 Europe market, 2018 - 2030 (USD Million)
• Fig. 49 Germany market, 2018 - 2030 (USD Million)
• Fig. 50 UK market, 2018 - 2030 (USD Million)
• Fig. 51 France market, 2018 - 2030 (USD Million)
• Fig. 52 Italy market, 2018 - 2030 (USD Million)
• Fig. 53 Spain market, 2018 - 2030 (USD Million)
• Fig. 54 Denmark market, 2018 - 2030(USD Million)
• Fig. 55 Sweden market, 2018 - 2030 (USD Million)
• Fig. 56 Norway market, 2018 - 2030 (USD Million)
• Fig. 57 Asia Pacific market, 2018 - 2030 (USD Million)
• Fig. 58 China market, 2018 - 2030 (USD Million)
• Fig. 59 Japan market, 2018 - 2030 (USD Million)
• Fig. 60 India market, 2018 - 2030 (USD Million)
• Fig. 61 Australia market, 2018 - 2030 (USD Million)
• Fig. 62 South Korea market, 2018 - 2030 (USD Million)
• Fig. 63 Thailand market, 2018 - 2030 (USD Million)
• Fig. 64 Latin America market, 2018 - 2030 (USD Million)
• Fig. 65 Brazil market, 2018 - 2030 (USD Million)
• Fig. 66 Mexico market, 2018 - 2030 (USD Million)
• Fig. 67 Argentina market, 2018 - 2030 (USD Million)
• Fig. 68 Middle East & Africa market, 2018 - 2030 (USD Million)
• Fig. 69 South Africa market, 2018 - 2030 (USD Million)
• Fig. 70 Saudi Arabia market, 2018 - 2030 (USD Million)
• Fig. 71 UAE market, 2018 - 2030 (USD Million)
• Fig. 72 Kuwait market, 2018 - 2030 (USD Million)

Biomarker Clinical Phase Outsourcing Services Market Growth & Trends:

The global biomarker clinical phase outsourcing services market size is expected to reach USD 27.17 billion by 2030, registering a CAGR of 20.6%, according to a new report by Grand View Research, Inc.. Increasing diagnostic applications of biomarkers, rapid advancements in OMICS technologies, a rise in research and development (R&D) funding from the government, and the shift toward precision medicine are a few of the factors driving the growth of the market.

The market is fragmented, with several key players having similar technological and processing capabilities. These companies offer various services related to biomarker testing, including assay development, sample analysis, data interpretation, and clinical trial support. This industry is characterized by intense competition driven by factors such as quality assurance, technological advancements, regulatory compliance, and the ability to offer high-value and diverse services.

Biomarkers are at the core of personalized medicine, enabling better patient care and more effective treatments. Hence, the shift towards precision medicine is another significant factor supporting demand for biomarker testing services, thereby augmenting market growth. For instance, in January 2022, Pfizer Inc. and Beam Therapeutics Inc. announced an exclusive four-year research collaboration agreement to develop precision medicines for rare genetic diseases.

The COVID-19 pandemic moderately impacted the market. The initial phase of the COVID-19 pandemic has significantly affected clinical trials due to travel restrictions, including trials involving biomarker testing services. However, the market recovered from the losses due to the rapid development of biomarkers for COVID-19 diagnosis. Biomarker-based tests, such as PCR assays targeting viral RNA and antigen tests detecting viral proteins, have been crucial for identifying and tracking the virus.

Biomarker Clinical Phase Outsourcing Services Market Report Highlights:

• Based on biomarker type, the surrogate endpoints segment accounted for the largest share of 56.0% in 2022. The segment's growth is driven by the growing demand for precision medicines and the rise in the number of clinical trials involving the use of biomarker analysis
• Based on therapeutic area, the oncology segment accounted for the largest share of 34.6% in 2022. High segment shares are majorly due to the increasing demand for cancer biomarkers for early detection and diagnosis of the condition
• Based on end-use, the biotechnology companies are anticipated to witness the highest CAGR of 20.8% across the analysis timeframe due to the increasing number of biopharmaceutical companies investing in developing novel biomarker testing services
• Asia Pacific is anticipated to witness the highest CAGR of 21.4% during the forecast time frame. High growth is primarily due to increasing number of Western pharmaceutical companies outsourcing their manufacturing activities to developing economies such as China and India

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Segment Definitions
  • 1.1.2. Biomarker Type
  • 1.1.3. Therapeutic Area
  • 1.1.4. End-use
• 1.2. Regional Scope
• 1.3. Estimates And Forecast Timeline
• 1.4. Objectives
  • 1.4.1. Objective-1
  • 1.4.2. Objective-2
  • 1.4.3. Objective-3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information Or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
  • 1.9.2. Parent Market Analysis
• 1.10. List Of Secondary Sources
• 1.11. List Of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Biomarker Clinical Phase Outsourcing Services Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing diagnostic applications of biomarkers
    • 3.2.1.2. Rise in R&D funding from the government
    • 3.2.1.3. Rapid advancements in technologies such as genomics, proteomics, and imaging
    • 3.2.1.4. The shift toward precision medicine
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High capital investment
    • 3.2.2.2. Challenges related to quality control
• 3.3. Biomarker Clinical Phase Outsourcing Services Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat Of New Entrant
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Biomarker Clinical Phase Outsourcing Services Market: Biomarker Type Estimates & Trend Analysis

• 4.1. Biomarker Clinical Phase Outsourcing Services Market, By Biomarker Type: Segment Dashboard
• 4.2. Biomarker Clinical Phase Outsourcing Services Market, By Biomarker Type: Movement Analysis
• 4.3. Biomarker Clinical Phase Outsourcing Services Market Estimates & Forecasts, By Biomarker Type, 2018 - 2030
  • 4.3.1. Predictive Biomarkers
    • 4.3.1.1. Predictive Biomarkers Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)
  • 4.3.2. Prognostic Biomarkers
    • 4.3.2.1. Prognostic Biomarkers Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)
  • 4.3.3. Safety Biomarkers
    • 4.3.3.1. Safety Biomarkers Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)
  • 4.3.4. Surrogate Endpoints
    • 4.3.4.1. Surrogate Endpoints Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)

Chapter 5. Biomarker Clinical Phase Outsourcing Services Market: Therapeutic Area Estimates & Trend Analysis

• 5.1. Biomarker Clinical Phase Outsourcing Services Market, By Therapeutic Area: Segment Dashboard
• 5.2. Biomarker Clinical Phase Outsourcing Services Market, By Therapeutic Area: Movement Analysis
• 5.3. Biomarker Clinical Phase Outsourcing Services Market Estimates & Forecasts, By Therapeutic Area, 2018 - 2030
  • 5.3.1. Oncology
    • 5.3.1.1. Oncology Biomarker Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)
  • 5.3.2. Neurology
    • 5.3.2.1. Neurology Biomarker Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)
  • 5.3.3. Cardiology
    • 5.3.3.1. Cardiology Biomarker Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)
  • 5.3.4. Autoimmune Diseases
    • 5.3.4.1. Autoimmune Diseases Biomarker Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)
  • 5.3.5. Others
    • 5.3.5.1. Others Biomarker Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)

Chapter 6. Biomarker Clinical Phase Outsourcing Services Market: End-use Estimates & Trend Analysis

• 6.1. Biomarker Clinical Phase Outsourcing Services Market, By End-use: Segment Dashboard
• 6.2. Biomarker Clinical Phase Outsourcing Services Market, By End-use: Movement Analysis
• 6.3. Biomarker Clinical Phase Outsourcing Services Market Estimates & Forecasts, By End-use, 2018 - 2030
  • 6.3.1. Pharmaceutical Companies
    • 6.3.1.1. Pharmaceutical Companies Biomarker Clinical Phase Outsourcing Services Market 2018 to 2030 (USD Million)
  • 6.3.2. Biotechnology Companies
    • 6.3.2.1. Biotechnology Companies Biomarker Clinical Phase Outsourcing Services Market 2018 to 2030 (USD Million)
  • 6.3.3. Others
    • 6.3.3.1. Others Biomarker Clinical Phase Outsourcing Services Market 2018 to 2030 (USD Million)

Chapter 7. Biomarker Clinical Phase Outsourcing Services Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2022 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. North America
  • 7.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030
• 7.5. Europe
  • 7.5.1. UK
    • 7.5.1.1. Key Country Dynamics
    • 7.5.1.2. Competitive Scenario
    • 7.5.1.3. Regulatory Framework
    • 7.5.1.4. UK Market Estimates and Forecasts, 2018 - 2030
  • 7.5.2. Germany
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Germany Market Estimates and Forecasts, 2018 - 2030
  • 7.5.3. France
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. France Market Estimates and Forecasts, 2018 - 2030
  • 7.5.4. Italy
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. Italy Market Estimates and Forecasts, 2018 - 2030
  • 7.5.5. Spain
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Competitive Scenario
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Spain Market Estimates and Forecasts, 2018 - 2030
  • 7.5.6. Denmark
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Competitive Scenario
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Denmark Market Estimates and Forecasts, 2018 - 2030
  • 7.5.7. Sweden
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Competitive Scenario
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030
  • 7.5.8. Norway
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Competitive Scenario
    • 7.5.8.3. Regulatory Framework
    • 7.5.8.4. Norway Market Estimates and Forecasts, 2018 - 2030
• 7.6. Asia Pacific
  • 7.6.1. Japan
    • 7.6.1.1. Key Country Dynamics
    • 7.6.1.2. Competitive Scenario
    • 7.6.1.3. Regulatory Framework
    • 7.6.1.4. Japan Market Estimates and Forecasts, 2018 - 2030
  • 7.6.2. India
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. India Market Estimates and Forecasts, 2018 - 2030
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. China Market Estimates and Forecasts, 2018 - 2030
  • 7.6.4. South Korea
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. South Korea Market Estimates and Forecasts, 2018 - 2030
  • 7.6.5. Australia
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Competitive Scenario
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030
  • 7.6.6. Thailand
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Competitive Scenario
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. Thailand Market Estimates and Forecasts, 2018 - 2030
• 7.7. Latin America
  • 7.7.1. Brazil
    • 7.7.1.1. Key Country Dynamics
    • 7.7.1.2. Competitive Scenario
    • 7.7.1.3. Regulatory Framework
    • 7.7.1.4. Brazil Market Estimates and Forecasts, 2018 - 2030
  • 7.7.2. Mexico
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Mexico Market Estimates and Forecasts, 2018 - 2030
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030
• 7.8. MEA
  • 7.8.1. South Africa
    • 7.8.1.1. Key Country Dynamics
    • 7.8.1.2. Competitive Scenario
    • 7.8.1.3. Regulatory Framework
    • 7.8.1.4. South Africa Market Estimates and Forecasts, 2018 - 2030
  • 7.8.2. Saudi Arabia
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Competitive Scenario
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030
  • 7.8.3. UAE
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Competitive Scenario
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. UAE Market Estimates and Forecasts, 2018 - 2030
  • 7.8.4. Kuwait
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Competitive Scenario
    • 7.8.4.3. Regulatory Framework
    • 7.8.4.4. Kuwait Market Estimates and Forecasts, 2018 - 2030

Chapter 8. Competitive Landscape

• 8.1. Market Participant Categorization
  • 8.1.1. Innovators
  • 8.1.2. Market Leaders
  • 8.1.3. Emerging Players
  • 8.1.4. Company Market Share Analysis, 2022
• 8.2. Company Profiles
  • 8.2.1. Laboratory Corporation of America Holdings
    • 8.2.1.1. Company Overview
    • 8.2.1.2. Financial Performance
    • 8.2.1.3. Service Benchmarking
    • 8.2.1.4. Strategic Initiatives
  • 8.2.2. Parexel International Corporation
    • 8.2.2.1. Company Overview
    • 8.2.2.2. Financial Performance
    • 8.2.2.3. Service Benchmarking
    • 8.2.2.4. Strategic Initiatives
  • 8.2.3. ICON plc
    • 8.2.3.1. Company Overview
    • 8.2.3.2. Financial Performance
    • 8.2.3.3. Service Benchmarking
    • 8.2.3.4. Strategic Initiatives
  • 8.2.4. Charles River Laboratories
    • 8.2.4.1. Company Overview
    • 8.2.4.2. Financial Performance
    • 8.2.4.3. Service Benchmarking
    • 8.2.4.4. Strategic Initiatives
  • 8.2.5. Proteome Sciences
    • 8.2.5.1. Company Overview
    • 8.2.5.2. Financial Performance
    • 8.2.5.3. Service Benchmarking
    • 8.2.5.4. Strategic Initiatives
  • 8.2.6. Fujirebio
    • 8.2.6.1. Company Overview
    • 8.2.6.2. Financial Performance
    • 8.2.6.3. Service Benchmarking
    • 8.2.6.4. Strategic Initiatives
  • 8.2.7. WuXi AppTec
    • 8.2.7.1. Company Overview
    • 8.2.7.2. Financial Performance
    • 8.2.7.3. Service Benchmarking
    • 8.2.7.4. Strategic Initiatives
  • 8.2.8. NorthEast BioAnalytical Laboratories LLC.
    • 8.2.8.1. Company Overview
    • 8.2.8.2. Financial Performance
    • 8.2.8.3. Service Benchmarking
    • 8.2.8.4. Strategic Initiatives
  • 8.2.9. Celerion
    • 8.2.9.1. Company Overview
    • 8.2.9.2. Financial Performance
    • 8.2.9.3. Service Benchmarking
    • 8.2.9.4. Strategic Initiatives
  • 8.2.10. GenScript ProBio
    • 8.2.10.1. Company Overview
    • 8.2.10.2. Financial Performance
    • 8.2.10.3. Service Benchmarking
    • 8.2.10.4. Strategic Initiatives